Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076199 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
A Phase 3 study of Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 877
- Enrollment target
- 20
- Study locations
NCT07076199: Recruiting Phase 3 study of Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S.
NCT07076199 is a Phase 3 study of Diabetes Mellitus, Type 1 that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 877 participants, below the 1,259-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07076199, a Phase 3 study of Diabetes Mellitus, Type 1, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 877 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.
Primary Outcome
Measured in percentage (%)-points.
Conditions Studied
Interventions
- DRUG Insulin aspart
- DRUG Insulin icodec
- DRUG Insulin glargine
Study Locations (20)
California
- John Muir Health - Concord
- Headlands Research California, LLC - Escondido
- Clinical Res of Central Ca - Fresno
- Providence Medical Foundation - Fullerton
- Scripps Whittier Diabetes Inst - La Jolla
- Loma Linda University Faculty Medical Clinics - Loma Linda
- Loma Linda University Faculty Medical Clinics - Loma Linda
- Pacific Clinical Studies - Los Alamitos
- Pasadena Clinical Trials - Pasadena
- WestenU Health - Pomona
- WestenU Health - Pomona
- Alliance Clinical Network - San Diego
- Mills Health Center - San Mateo
- Center for Endocrine DM and Metabolic Disorders - Santa Clarita
- University Clin Investigators - Tustin
- Diablo Clinical Research, Inc. - Walnut Creek
Colorado
- Denver Endocrinology Diabetes and Thyroid Center - Englewood
- Optumcare Clinical Trials,LLC-Golden - Golden
Alabama
- Cullman Clinical Trials - Cullman
Florida
- Northeast Research Institute - Fleming Island
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 877 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2026-12-28 |
| Phase | Phase 3 |
What NCT07076199 shows while recruiting
NCT07076199 is an interventional study that assigns participants to a tested intervention. The registered 877 participants enrollment target is mid-sized for trials with a published cap, below the 1,259-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 3 interventions - of which Insulin aspart is the first listed.
NCT07076199 names 20 study sites across 4 states, led by California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT07076199 about?
NCT07076199 is a clinical study titled "A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes". This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargi...
What is the current status of trial NCT07076199?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 877 participants. The study started on 2025-08-11. Estimated completion is 2026-12-28.
What conditions does trial NCT07076199 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT07076199?
The interventions under investigation include: Insulin aspart (DRUG), Insulin icodec (DRUG), Insulin glargine (DRUG).
Who is sponsoring clinical trial NCT07076199?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076199 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07076199's enrollment target sits among peer trials
877 8th of 118 higher than 111 of 118 other Diabetes Mellitus, Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
RECRUITING · Phase 3
-
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
RECRUITING · Phase 3
-
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
RECRUITING · Phase 3
-
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
RECRUITING · Phase 3
-
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
RECRUITING · Phase 3
-
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06627647 · 878 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI